Prof. Joerg Schefold of the Bern University Hospital, Switzerland talks to NEN about his research and recent published findings where he investigated the predictive value of IDO activity, tryptophan levels, and downstream catabolites in a neuroendocrine neoplasm patient population.
Interview by Dr. Julie Ann Lough
Pschowski R, Pape UF, Fusch G, Fischer C, Jann H, Baur A, Arsenic R, Wiedenmann B, von Haehling S, Pavel M, Schefold JC. Increased Activity of the Immunoregulatory Enzyme Indoleamine-2,3-Dioxygenase with Consecutive Tryptophan Depletion Predicts Death in Patients with Neuroendocrine Neoplasia. Neuroendocrinology. 2017;104(2):135-144.